Inbiome welcomes Professor Dr. Carl Wittwer to Advisory Board in Amsterdam

On September 20, 2024, Inbiome, a leader in molecular diagnostics, announced the appointment of Professor Dr. Carl Wittwer to its Advisory Board in Amsterdam. Dr. Wittwer is a prominent figure in PCR technology, known for his extensive contributions to the field, including over 50 U.S. patents and more than 200 scientific publications. His expertise is expected to significantly enhance Inbiome's innovative diagnostic solutions, particularly in the area of pathogen identification. Inbiome is developing a new PCR technology that allows for the simultaneous detection of hundreds of bacterial pathogens in a single test, which is a major advancement over traditional methods that can take days to yield results. This technology aims to address the urgent need for faster diagnostics in healthcare, where delays can lead to worsened patient outcomes. With bacterial infections responsible for a substantial number of human deaths, the importance of rapid diagnostics cannot be overstated. The company collaborates with industry leaders and academic institutions in both the U.S. and Europe to further its research and product development. Inbiome's work has garnered recognition from the European Innovation Council, which provided an EIC Accelerator grant in 2023 to support the commercialization of its first in vitro diagnostic device. This funding is crucial for advancing their go-to-market strategy. The addition of Dr. Wittwer to the advisory board is seen as a pivotal move for Inbiome, as his guidance will be instrumental in expanding the capabilities of their technology and bringing it to a global market. His enthusiasm for Inbiome's innovative approach highlights the potential impact on healthcare diagnostics and the fight against antimicrobial resistance.